Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
IM

NASDAQ · IMCR

Immunocore Holdings plc

Healthcare · Biotechnology

$33.58

Down-$0.89 (-2.58%)

Updated Sep 11, 2026, 4:59 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.81B
P/E ratio
-63.88
Dividend yield
0.00%
52-week range
$27.56 – $37.95
Volume
237.1K
Avg. volume
310.24K

Price performance

IMCR price history

1M range · 20 trading sessions · Daily adjusted prices

IMCR closed at $33.58 after 20 trading sessions, down 1.81% for the selected period.

Last close
$33.58
Period change
-1.81%
Period low
$33.58
Period high
$37.57
Daily close
View OHLC price history
IMCR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$34.16$34.375$33.13$33.58237.1K
Sep 9, 2026$35.16$35.345$34.29$34.47337.08K
Sep 8, 2026$35.83$35.83$35.0401$35.36468.74K
Sep 4, 2026$37.24$37.43$35.975$36.13231.71K
Sep 3, 2026$37.20$37.66$36.70$37.57245.97K
Sep 2, 2026$37.17$37.9516$36.23$37.37220.69K
Sep 1, 2026$36.50$36.98$35.85$36.86790.81K
Aug 31, 2026$36.36$36.405$35.4967$36.32271.61K
Aug 28, 2026$36.64$36.78$36.05$36.62300.33K
Aug 27, 2026$36.82$37.11$36.46$36.75270.34K
Aug 26, 2026$37.25$37.25$36.70$37.12255.28K
Aug 25, 2026$36.76$37.50$36.46$37.40257.34K
Aug 24, 2026$36.76$36.93$35.72$36.61371.18K
Aug 21, 2026$36.70$36.98$35.68$36.88329.45K
Aug 20, 2026$36.60$36.60$35.08$36.28590.25K
Aug 19, 2026$36.16$37.44$35.42$36.86677.78K
Aug 18, 2026$35.09$36.44$34.775$36.02620.06K
Aug 17, 2026$34.25$35.27$33.865$35.05261.46K
Aug 14, 2026$34.02$34.39$33.50$34.21195.19K
Aug 13, 2026$34.69$35.19$33.925$34.20329.52K

Latest IMCR news

The latest Smart Investors Daily articles mentioning IMCR.

Stock researchCompany · Overview

IMCR research

Overview

Company profile and research snapshot.

Company profile

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$48.00
Implied upside
—
Analysts
—
IMCR recent ratings
DateFirmRatingTarget
Aug 21, 2026JP MorganOverweight—
Aug 3, 2026MizuhoNeutral—
Apr 20, 2026HC Wainwright & Co.Buy—
Apr 14, 2026HC Wainwright & Co.Buy—
Mar 16, 2026JefferiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By